A prospective study of unfractionated heparin therapy in dogs with primary immune-mediated hemolytic anemia

Journal of the American Animal Hospital Association

Volumn 45, Issue 3, 2009, Pages 125-133

  Breuhl, Elizabeth L ^a   Moore, George ^a   Brooks, Marjory B ^b   Scott Moncrieff, J Catharine ^a  

^a PURDUE UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; HEPARIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD; DOG; DOG DISEASE; DRUG ANTAGONISM; FEMALE; MALE; MORTALITY; PILOT STUDY; PROSPECTIVE STUDY; SURVIVAL; THROMBOEMBOLISM; TIME; TREATMENT OUTCOME; UNITED STATES;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTICOAGULANTS; DOG DISEASES; DOGS; FACTOR XA; FEMALE; HEPARIN; ILLINOIS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 68149170813     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0450125     Document Type: Article

References (42)

1. Scott-Moncrieff JC, Treadwell NG, McCullough SM, Brooks MB. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001;37(3):220-227.
2. Johnson LR. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 1999;13(4):338-345.
3. Klein MK, Dow SW, Rosychuk RA. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc 1989;195(2):246-250.
4. McManus PM, Craig LE. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 2001;218(8):1308-1313.
5. Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 2002;16(5):504-509.
6. Lowe GD. Virchow's triad revisited: Abnormal flow. Pathophysiol Haemost Thromb 2003;33:455-457.
7. Silver D, Vouyouka A. The caput medusae of hypercoagulability. J Vasc Surg 2000;31:396-405.
8. Mischke R. Disturbances in hemostasis as a complication of autoimmune hemolytic anemia in the dog. Dtsch Tierarztl Wochenschr 1998;105:13-16.
9. Thompson MF, Scott-Moncrieff JC, Brooks MB. Effect of a single plasma transfusion on thromboembolism in 13 dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2004;40(6):446-454.
10. Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: unfractionated heparin and low molecular weight heparin. Ann Pharmacother 2005;39:1275-1285.
11. McGlasson DL, Kaczor DA, Krasuski RA, Campbell CL, Kostur MR, Adinaro JT. Effects of pre analytic variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagul Fibrinolysis 2005;16:173-176.
12. Mischke RH, Schuttert C, Grebe SI. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 2001;62(12):1887-1891.
13. Diquélou A, Barbaste C, Gabaig AM, et al. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. Vet Clin Pathol 2005;34(3):237-242.
14. Rosborough TK, Shepherd MF, Pharm D. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 2004;24:713-719.
15. Hirsh J, Raschke R. Heparin and low molecular weight heparin. The seventh AACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:188S-203S.
16. Kitchen S, Preston FE. The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996;75(5): 734-739.
17. Hirsh J. Heparin. N Engl J Med 1991;324(22):1565-1574.
18. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335(24):1816-1828.
19. Ewenstein BM. Antithrombotic agents and thromboembolic disease. N Engl J Med 1997;337(19):1383-1384.
20. Behrend EN, Kemppainen RJ. Glucocorticoid therapy. Pharmacology, indications, and complications. Vet Clin North Am Small Anim Pract 1997;27(2):187-213.
21. Giger U. Regenerative anemias caused by blood loss of hemolysis. In: Ettinger S, Feldman E, eds. Textbook of Veterinary Internal Medicine. 6th ed. St. Louis: Elsevier Saunders, 2005:1886-1907.
22. Brooks MB. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Vet Clin Pathol 2004;33:208-214.
23. Kellerman DL, Lewis DC, Bruyette DS, et al. Determination of and monitoring of a therapeutic heparin dosage in the dog. J Vet Intern Med 1995;9:187.
24. Stokol T, Brooks MB, Erb HN. Effect of citrate concentration on coagulation test results in dogs. J Am Vet Med Assoc 2000;217:1672-1677.
25. Kottke-Marchant K, Duncan A. Antithrombin deficiency issues in laboratory diagnosis. Arch Pathol Lab Med 2002;126(11):1326-1336.
26. Hellebrekers LJ. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. Am J Vet Res 1985;46:1460-1462.
27. Giger U. Regenerative anemias caused by blood loss or hemolysis. Textbook of Veterinary Internal Medicine. St. Louis: Elsevier Saunders, 2005:1886-1907.
28. Miller E. CVT update: diagnosis and treatment of immune-mediated hemolytic anemia. In: Bonagura JD, ed. Kirk's Current Veterinary Therapy. Philadelphia: Saunders, 2000:427-434.
29. Weinkle TK, Center SA, Randolph JF, Warner KL, Barr SC, Erb HN. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005;226(11):1869-1880.
30. Rozanski EA, Hughes D, Scotti M, et al. The effect of heparin and fresh frozen plasma on plasma antithrombin III activity, prothrombin time and activated partial thromboplastin time in critically ill dogs. J Vet Emerg Crit Care 2001;11(1):15-21.
31. Young E, Podor TJ, Venner T, Hirsh J. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997;17:1568-1574.
32. Cosmi B, Fredengurgh JC, Rischke J, Hirsh J, Young E, Weitz JI. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low molecular weight heparin and dermatan sulfate. Circulation 1997;95:118-124.
33. Warkentin TE. The paradoxes of heparin-induced thrombocytopenia. Blood Therapies in Medicine 2001;1:74-80.
34. Plumb D. Plumb's Veterinary Drug Handbook. 5th ed. Stockholm, Wisconsin: Blackwell Publishing, 2005.
35. Freedman MD. Pharmacodynamics, clinical indications, and adverse effects of heparin. J Clin Pharmacol 1992;32:584-596.
36. Mischke R, Jacobs C. The monitoring of heparin administration by screening tests in experimental dogs. Res Vet Sci 2001;70(2): 101-108.
37. Levine MN, Hirsh J, Gent M. A randomized trial comparing aPTT with heparin assay in patient with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154: 49-56.
38. Lee MS, Menon V, Schappert J, Wilentz JR, Singh V, Hochman JS. Establishing new target range for unfractionated heparin for acute coronary syndromes. J Thromb Thrombolysis 2004;17:121-126.
39. Klag AR, Giger U, Shofer FS. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med Assoc 1993;202(5):783-788.
40. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999;35(5):384-391.
41. Burgess K, Moore A, Rand W, Cotter SM. Treatment of immunemediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 2000;14(4):456-462.
42. Mason N, Duval D, Shofer FS, Giger U. Cyclophosphamide exerts no beneficial effect over prednisone alone in the treatment of acute immune-mediated hemolytic anemia in dogs. J Vet Intern Med 2003;17:206-212.